Dr. Packiam is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany Street
New Brunswick, NJ 08903Phone+1 732-235-2465
Summary
- Vignesh Packiam, MD received his medical degree from the University of Pittsburgh, followed by residency at the University of Chicago, and a two-year Society of Urologic Oncology accredited fellowship at Mayo Clinic. Dr. Packiam treats genitourinary malignancies including bladder, prostate, kidney, and testicular cancer, and is experienced in open and robotic surgery. He has a background in clinical trials and feels it is important to educate his patients about all available options. He has a clinical interest in bladder cancer and supports patient centered groups such as the Bladder Cancer Advocacy Network. He is an active member of numerous cancer societies, serves as a reviewer for multiple urology journals, and has authored over 100 peer-reviewed articles and book chapters.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Minimally Invasive Urologic Surgery, 2018 - 2020
- University of ChicagoResidency, Urology, 2012 - 2018
- University of Pittsburgh School of MedicineClass of 2012
- University of Wisconsin-MadisonB.S., Biology, Philosophy, Dean's Scholar, 2004 - 2008
Certifications & Licensure
- IA State Medical License 2020 - 2025
- NJ State Medical License 2023 - 2025
- MN State Medical License 2018 - 2021
- WI State Medical License 2018 - 2021
- IL State Medical License 2013 - 2020
- American Board of Urology Urology
Publications & Presentations
PubMed
- 5 citationsSequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectivene...Laura Bukavina, Spencer Bell, Vignesh T Packiam, Marc Smaldone, Philip Abbosh
Urologic Oncology. 2023-09-01 - 13 citationsCost-Effectiveness Analysis of Pembrolizumab for Bacillus Calmette-Guérin-Unresponsive Carcinoma In Situ of the Bladder.Kevin Wymer, Vidit Sharma, Christopher S. Saigal, Karim Chamie, Mark S. Litwin
The Journal of Urology. 2021-05-01 - 149 citationsAn open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasi...Vignesh T. Packiam, Donald L. Lamm, Daniel A. Barocas, Andrew Trainer, Benjamin Fand
Urologic Oncology. 2017-07-26
Press Mentions
- Gemcitabine-Docetaxel Effective Alternative to BCG in NMIBCMarch 7th, 2023
- Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients with Non–Muscle-Invasive Bladder Cancer Amid BCG ShortageMarch 1st, 2023
- Given the Lack of Standard BCG Treatments Worldwide, an Alternative Bladder Cancer Treatment Is EvolvingFebruary 28th, 2023
- Join now to see all
External Links
- Websitehttps://www.cinj.org/vignesh-t-packiam-md
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: